Glaxo forms vaccine JV with Chinese firm

GlaxoSmithKline and Shenzhen Neptunus will create a joint venture to make influenza vaccines for Greater China.

Drug company GlaxoSmithKline GSK has formed a joint venture with Chinese firm Shenzhen Neptunus Interlong Bio-Technique Company to develop and manufacture influenza vaccines for the Chinese market.

The JV will make influenza vaccines for China, Hong Kong and Macau, including vaccines for seasonal, pre-pandemic and pandemic influenza.  

Shenzhen Neptunus will own 60% of the JV and will contribute cash and assets to the tune of approximately $47 million. The Chinese firm will also provide local manufacturing capacity...

To continue reading, please login or register for free

Print Edition

FinanceAsia Print Edition